AVTX insider trading — Avalo Therapeutics, Inc.
Over the last 90 days, insiders at Avalo Therapeutics, Inc. (AVTX) made 0 open-market purchases worth $0 and 1 open-market sale worth $52K, making them net sellers by $52K. The largest sale was by Riley Jennifer (Chief Strategy Officer), who sold 2,655 shares for $52K on Aug 11, 2026.
Updated Oct 16, 2026.
Recent AVTX insider transactions
Every Form 4 filed by Avalo Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | M · Option exercise · 10b5-1 | Direct | 12,394 | $9.88 | $122K | Form 4 |
| Sep 16, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | S · Sale · 10b5-1 | Direct | 12,394 | $16.33 | $202K | Form 4 |
| Sep 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | M · Option exercise · 10b5-1 | Direct | 10,185 | $8.04 | $82K | Form 4 |
| Sep 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | S · Sale · 10b5-1 | Direct | 10,185 | $17.62 | $179K | Form 4 |
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 679 | $8.04 | $5K | Form 4 |
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 679 | $20.00 | $14K | Form 4 |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | M · Option exercise · 10b5-1 | Direct | 31,031 | $9.88 | $307K | Form 4 |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | S · Sale · 10b5-1 | Direct | 31,031 | $20.05 | $622K | Form 4 |
| Aug 17, 2026 | Doyle Mittie | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 1,000 | $12.65 | $13K | Form 4 |
| Aug 17, 2026 | Doyle Mittie | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 1,000 | $20.00 | $20K | Form 4 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | M · Option exercise · 10b5-1 | Direct | 40,821 | $9.88 | $403K | Form 4 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | S · Sale · 10b5-1 | Direct | 41,694 | $19.86 | $828K | Form 4 |
| Aug 11, 2026 | Riley Jennifer | Chief Strategy Officer | S · Sale | Direct | 2,655 | $19.59 | $52K | Form 4 |
| Aug 10, 2026 | Doyle Mittie | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 679 | $8.04 | $5K | Form 4 |
| Aug 10, 2026 | Doyle Mittie | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 679 | $20.00 | $14K | Form 4 |
| Jul 27, 2026 | Doyle Mittie | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 1,000 | $12.65 | $13K | Form 4 |
| Jul 27, 2026 | Doyle Mittie | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 1,000 | $20.00 | $20K | Form 4 |
AVTX insider trading FAQ
Are insiders buying AVTX stock?
Not on the open market. In the last 90 days, Avalo Therapeutics, Inc. insiders made no open-market purchases, and 1 open-market sale totaling $52K. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading AVTX?
Recent sellers: Riley Jennifer.
Where does AVTX insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.